"目錄號(hào): HY-15240
DCC-2618 是一種有效的c-Kit和c-Met抑制劑，IC50值 <200 nM摄咆。
相關(guān)產(chǎn)品
Sorafenib-Pexidartinib-Cabozantinib-Crizotinib-Imatinib Mesylate-Pazopanib-BMS 777607-Foretinib-Dovitinib-PHA-665752-Tivantinib-Savolitinib-INCB28060-Masitinib-LY2801653-
生物活性
Description
DCC-2618 is a potent inhibitor ofc-Kitandc-MetwithIC50s of <200 nM.
IC50& Target
IC50: <200 nM (c-Met), <200 nM (c-Kit), <2 μM (KDR), <10 μM (PDGFRα), <10 μM (PDGFRβ)[1]
In Vitro
DCC-2618 is a c-Kit and c-Met inhibitor extracted from patent 2010051373A1, compound example 45, has an IC50of <200 nM. DCC-2618 also inhibits KDR, PDGFR α and β with IC50s of <2 μM, <10 μM and <10 μM, respectively[1].
Clinical Trial
Deciphera Pharmaceuticals LLC
Gastrointestinal Stromal Tumors-Aggressive Systemic Mastocytosis-Advanced Cancers
October 2015
Phase 1
View MoreCollapse
References
